J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Phase 2 – studying effectiveness and dosage
Conditions:
Ulcerative Colitis
Sponsor: Eli Lilly & Co.
trial.available_in:
БГ
Overview
Trial status: Authorised
The proportion of participants who achieve clinical remission with mMS at Week 12
Who can participate
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 75 participants
БГ